Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tenvie Therapeutics Inc. is managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio is distributed across 4 distinct art units and 4 distinct examiners. REILLY, SOPHIA JANE is the busiest examiner for the company, overseeing 1 pending action. This structure indicates that every pending action is being handled by a different examiner in a different art unit, requiring a broad and flexible prosecution strategy to address the various technical and procedural requirements.
With 4 pending office actions split among 4 distinct examiners, the company avoids the risk of a single examiner's bias affecting multiple cases. Each of the 4 distinct art units will have its own specific focus within the Biotechnology & Pharmaceuticals field, necessitating a tailored approach for each application. REILLY, SOPHIA JANE, while listed as the busiest examiner, holds no more influence than the other three examiners, as each manages exactly 1 pending action. Practitioners should focus on the individual tendencies of all 4 distinct examiners to maximize the chances of allowance across the entire portfolio. This distributed workload across 4 distinct art units reflects a technically diverse set of pharmaceutical innovations.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.0% | +49.4% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| SHIM, DAVID M. | 1 | 58.8% | +58.5% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18837817 | COMPOUNDS, COMPOSITIONS, AND METHODS | INAM, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18041539 | COMPOUNDS, COMPOSITIONS AND METHODS | SHIM, DAVID M. | 19d overdue |
| 18001695 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDOWELL, BRIAN E | 72d |
| 18852324 | COMPOUNDS, COMPOSITIONS, AND METHODS | REILLY, SOPHIA JANE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1622 | 1 |
| 1626 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18852324 | COMPOUNDS, COMPOSITIONS, AND METHODS | REILLY, SOPHIA JANE | 1627 | §103§112DP | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18837817 | COMPOUNDS, COMPOSITIONS, AND METHODS | INAM, SAHAR | 1622 | §112 | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18041539 | COMPOUNDS, COMPOSITIONS AND METHODS | SHIM, DAVID M. | 1626 | §103Other | Final Rejection | 19d overdue | Pending | Feb 13, 2023 |
| 18001695 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDOWELL, BRIAN E | 1624 | §112 | Final Rejection | 72d | Pending | Dec 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTenvie Therapeutics Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Sophia Jane Reilly has the most, with 1 of Tenvie Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
